Market Cap 20.86B
Revenue (ttm) 9.68B
Net Income (ttm) 1.63B
EPS (ttm) N/A
PE Ratio 8.97
Forward PE 9.09
Profit Margin 16.87%
Debt to Equity Ratio 0.36
Volume 1,010,000
Avg Vol 1,608,614
Day's Range N/A - N/A
Shares Out 146.62M
Stochastic %K 10%
Beta 0.13
Analysts Sell
Price Target $172.36

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
tgTWE2
tgTWE2 Oct. 18 at 5:23 AM
?? High-conviction cluster — risk-defined entries only! ???? ?? Portfolio: $BIIB $C $QCOM $VRTX $MRNA ?? Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. BIIB shows relative strength; C is base-building; QCOM is a stealth accumulator; VRTX offers sector exposure; MRNA provides stability. ?? Execution: Execution: define stop levels, use partial profit-taking on initial leg. ?? ???? #AlphaHunt #Tactical ???? ?? Source: https://stocktwits.com/MichaelFreeman6940/message/632828614
0 · Reply
StockAutoPro
StockAutoPro Oct. 18 at 3:49 AM
$BIIB: Buy target $151.89 Sell target $161.58 Strong Alzheimer's drug potential may drive significant sector growth.
0 · Reply
lecorb
lecorb Oct. 17 at 1:06 PM
$SNY Sanofi and Insmed among winners of EU drug recommendations this week $INSM $BIIB $REGN $AGIO & More. https://seekingalpha.com/news/4505183-sanofi-insmed-among-winners-chmp-recommendations?mailingid=42050924&messageid=2900&position=rta_news_most_popular_main_0_title&serial=42050924.22569&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=42050924.22569
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 12:00 AM
Enter: $BIIB NOV 07 2025 $144 CALLS Buy in Price: $8.80 - $11.05 Take Profit: $20.77 Stop Bleeding: $9.72 ROI Potential: 88% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 16 at 5:19 PM
$BIIB Share Price: $143.33 Contract Selected: Nov 07, 2025 $144.0 Calls Buy Zone: $4.93 – $6.09 Target Zone: $7.97 – $9.75 Potential Upside: 53% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SR_JACK
SR_JACK Oct. 14 at 9:07 PM
Biogen Expects Q3 Charge Of $0.01 Per Share Due To $2M In Acquired R&D, Upfront, And Milestone Expenses, Impacting Both GAAP And Non-GAAP Earnings $BIIB
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:15 PM
Scotiabank updates rating for Biogen ( $BIIB ) to Sector Outperform, target set at 304 → 275.
1 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:11 PM
RBC Capital updates rating for Biogen ( $BIIB ) to Outperform, target set at 213 → 208.
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:07 PM
RBC Capital has updated their rating for Biogen ( $BIIB ) to Outperform with a price target of 340.
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:01 PM
Needham has updated their rating for Biogen ( $BIIB ) to Buy with a price target of 321.
0 · Reply
Latest News on BIIB
Biogen's Comeback: Why The Bulls Are Finally Winning Again

Oct 9, 2025, 10:54 AM EDT - 9 days ago

Biogen's Comeback: Why The Bulls Are Finally Winning Again


BIIB Stock: Is Biogen Still A Buy After The 14% Spike?

Oct 3, 2025, 8:50 AM EDT - 15 days ago

BIIB Stock: Is Biogen Still A Buy After The 14% Spike?


Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 2:24 PM EDT - 2 months ago

Biogen Inc. (BIIB) Q2 2025 Earnings Call Transcript


Biogen to invest $2 billion more in North Carolina

Jul 21, 2025, 7:41 AM EDT - 3 months ago

Biogen to invest $2 billion more in North Carolina


Biogen: Investors Are Missing The Bigger Picture

Jun 22, 2025, 10:27 PM EDT - 4 months ago

Biogen: Investors Are Missing The Bigger Picture


tgTWE2
tgTWE2 Oct. 18 at 5:23 AM
?? High-conviction cluster — risk-defined entries only! ???? ?? Portfolio: $BIIB $C $QCOM $VRTX $MRNA ?? Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. BIIB shows relative strength; C is base-building; QCOM is a stealth accumulator; VRTX offers sector exposure; MRNA provides stability. ?? Execution: Execution: define stop levels, use partial profit-taking on initial leg. ?? ???? #AlphaHunt #Tactical ???? ?? Source: https://stocktwits.com/MichaelFreeman6940/message/632828614
0 · Reply
StockAutoPro
StockAutoPro Oct. 18 at 3:49 AM
$BIIB: Buy target $151.89 Sell target $161.58 Strong Alzheimer's drug potential may drive significant sector growth.
0 · Reply
lecorb
lecorb Oct. 17 at 1:06 PM
$SNY Sanofi and Insmed among winners of EU drug recommendations this week $INSM $BIIB $REGN $AGIO & More. https://seekingalpha.com/news/4505183-sanofi-insmed-among-winners-chmp-recommendations?mailingid=42050924&messageid=2900&position=rta_news_most_popular_main_0_title&serial=42050924.22569&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=42050924.22569
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 17 at 12:00 AM
Enter: $BIIB NOV 07 2025 $144 CALLS Buy in Price: $8.80 - $11.05 Take Profit: $20.77 Stop Bleeding: $9.72 ROI Potential: 88% Exit Within: 3 Weeks https://moneygroup.us/alerts
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 16 at 5:19 PM
$BIIB Share Price: $143.33 Contract Selected: Nov 07, 2025 $144.0 Calls Buy Zone: $4.93 – $6.09 Target Zone: $7.97 – $9.75 Potential Upside: 53% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SR_JACK
SR_JACK Oct. 14 at 9:07 PM
Biogen Expects Q3 Charge Of $0.01 Per Share Due To $2M In Acquired R&D, Upfront, And Milestone Expenses, Impacting Both GAAP And Non-GAAP Earnings $BIIB
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:15 PM
Scotiabank updates rating for Biogen ( $BIIB ) to Sector Outperform, target set at 304 → 275.
1 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:11 PM
RBC Capital updates rating for Biogen ( $BIIB ) to Outperform, target set at 213 → 208.
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:07 PM
RBC Capital has updated their rating for Biogen ( $BIIB ) to Outperform with a price target of 340.
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:01 PM
Needham has updated their rating for Biogen ( $BIIB ) to Buy with a price target of 321.
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 7:00 PM
Needham updates rating for Biogen ( $BIIB ) to Buy, target set at 321.
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 6:59 PM
Needham has adjusted their stance on Biogen ( $BIIB ), setting the rating to Buy with a target price of 321.
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 6:57 PM
Needham updates rating for Biogen ( $BIIB ) to Buy, target set at 305.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 14 at 6:13 PM
Enter: $BIIB NOV 07 2025 $148 CALLS Buy in Price: $8.20 - $9.90 Take Profit: $23.66 Stop Bleeding: $8.71 ROI Potential: 139% Exit Within: 1 Weeks https://moneygroup.us/alerts
0 · Reply
theDIOyears
theDIOyears Oct. 13 at 12:48 PM
$XTNT $BIIB $PHAT $BVS $LGCY In traders jail for the next 90 days. Pray for me.
1 · Reply
pkmatov
pkmatov Oct. 13 at 8:59 AM
0 · Reply
BostonNorth
BostonNorth Oct. 12 at 7:46 PM
$SPRY $NDAQ $BIIB @Stocktwits
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 12 at 4:27 PM
Enter: $BIIB OCT 31 2025 $147 CALLS Buy in Price: $3.05 - $6.10 Take Profit: $6.10 Stop Bleeding: $2.68 ROI Potential: 100% Exit Within: 88 Minutes https://moneygroup.us/alerts
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 11 at 3:29 PM
Enter: $BIIB OCT 31 2025 $147 CALLS Buy in Price: $3.05 - $6.10 Take Profit: $6.10 Stop Bleeding: $2.68 ROI Potential: 100% Exit Within: 88 Minutes https://moneygroup.us/alerts
0 · Reply
Bulltard69
Bulltard69 Oct. 11 at 1:57 PM
$OKLO congrats OKLO bulls. You just surpassed $BIIB in market cap. Biogen only does $10B of revenue a year. And they are just a boring pharmaceutical company, not a super cool, hip, nuclear startup. Oklo makes $0 revenue a year but they have super sweet 3d rendering of a fission plant that *Might* start generating revenue by 2030. Have you seen that yet?? #winning
1 · Reply
SuperGreenToday
SuperGreenToday Oct. 11 at 1:30 AM
$BIIB Share Price: $146.61 Contract Selected: Nov 07, 2025 $150 Calls Buy Zone: $5.10 – $6.30 Target Zone: $8.91 – $10.89 Potential Upside: 65% ROI Time to Expiration: 27 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Oct. 10 at 5:36 PM
Morgan Stanley has updated their rating for Biogen ( $BIIB ) to Equal-Weight with a price target of 149.
0 · Reply